keytruda
New Keytruda dosing schedule rejected in six cancers by the FDA
February 20, 2020Sales and Marketing Cancer, FDA, MSD, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda has been stopped in its tracks by the FDA after the US regulator rejected its application …
NICE gives initial ‘no’ to NHS England for kidney cancer drug
February 18, 2020Manufacturing and Production NHS England, NICE, clinical trials, inlyta, keytruda
The National Institute for Health and Care Excellence (NICE) has not recommended Keytruda (pembrolizumab) and Inlyta (axitinib) for the treatment …
NICE does not recommend cancer drug combination to the NHS
February 13, 2020Business Services Cancer, Kidney cancer, NHS, NICE, keytruda, kidney disease
NICE has published draft guidance that does not recommend a new drug combination to combat untreated advanced renal cell carcinoma …
Seattle Genetics and Astellas unveil positive results for Padcev-Keytruda treatment for bladder cancer
February 12, 2020Research and Development Astellas, Cancer, Seattle Genentics, bladder, bladder cancer, keytruda, monotherapy
Seattle Genetics and Astellas reported positive results from their trials of Padcev plus Keytruda in treating bladder cancer. The data …
NICE shoots down Keytruda in head and neck cancer over data concerns
January 16, 2020Sales and Marketing Cancer, NHS, NICE, UK, keytruda, pharma
It has been revealed that NICE has chosen to reject MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) for routine use on the …
MSD’s Keytruda chalks up bladder cancer approval in the US
January 9, 2020Sales and Marketing Cancer, MSD, bladder cancer, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has added another US approval to its repertoire with the news that FDA has awarded …
Bittersweet Phase 3 Keytruda data hits one of two goals in extensive stage small cell lung cancer
January 7, 2020Manufacturing and Production, Research and Development MSD, keytruda
MSD has lifted the curtain on new Phase 3 data on the efficacy of its blockbuster immunotherapy Keytruda, in combination …
FDA advisory panel back Merck & Co.’s Keytruda treatment for bladder cancer
December 18, 2019Research and Development FDA, Merck, Merck and Co, NHS, NICE, keytruda
An FDA advisory committee voted 9 to 4 in favour of recommending Merk and Co’s Keytruda (pembrolizumab) for treatment in …
Prostate Cancer ‘super responders’ could live for two more years on Keytruda
November 28, 2019Research and Development Cancer, immunotherapy, keytruda, oncology, prostate cancer
Men with advanced prostate cancer, who have exhausted all treatment options, could use the immunotherapy Keytruda (pembrolizumab) to live for …
Europe approves Keytruda for first-line head and neck squamous cell carcinoma, as a monotherapy or combo
November 20, 2019Research and Development, Sales and Marketing Cancer, keytruda, pharma
MSD’s top-selling immunotherapy Keytruda (pembrolizumab) has secured another approval from the European Commission, this time in the first-line treatment of …
Keytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor market, report reveals
November 19, 2019Manufacturing and Production, Sales and Marketing Bristol-Myers Squibb, MSD, keytruda, opdivo, pharma
MSD’s Keytruda (pembrolizumab) overtook Bristol-Myers Squibb’s (BMS) blockbuster drug Opdivo (nivolumab) in total sales in the third quarter of 2019 …
Scotland approves first-line NHS use of MSD’s Keytruda combo for advanced non-small cell lung cancer
October 7, 2019Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, keytruda, lung cancer, pharma
The Scottish Medicines Consortium (SMC) has announced its decision to accept MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) in combination with pemetrexed …
US, Canada and Australia simultaneously fast-track Keytruda/Lenvima combo for endometrial cancer
September 18, 2019Research and Development, Sales and Marketing Australian Therapeutic Goods Administration, Cancer, FDA, Health Canada, Lenvima, keytruda, pharma
The FDA has acted under a new initiative in collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, …
MSD’s Keytruda approved for first-line lung cancer use on NHS Scotland
September 10, 2019Manufacturing and Production, Sales and Marketing Cancer, MSD, SMC, Scotland, keytruda, lung cancer, pharma
MSD and lung cancer patients will be celebrating the news that the pharma giant’s immunotherapy Keytruda (pembrolizumab) has been accepted …
Keytruda scores EU approval in combination with Inlyta for first-line advanced renal cell carcinoma
September 4, 2019Research and Development, Sales and Marketing EU, Europe, MSD, keytruda, pharma, renal cell carcinoma
The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the …
